In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that list that have the biggest upside potential to the posted price targets. For these five stocks – including “an off-the-radar idea for investors who are more aggressive” from the gene editing space – CLICK HERE.